 |
26 Diseases |  |
58 Trials |
|
58 Trials |  |
4692 News |  |
| «12...2829303132333435363738...6263» |
- Tivicay (dolutegravir) / ViiV Healthcare
Patient-reported treatment satisfaction and quality of life among people living with HIV following the introduction of Dolutegravir-based ART regimens in Ukraine (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_377;
However, positive relationships between DTG use and other PROs, as seen in clinical trials of DTG, were not evident in this real-world study. While the results indicate modestly favorable effects of ART Optimization, there is clearly a need for complementary interventions to improve PROs among disadvantaged ART patients in Ukraine.
- Prezista (darunavir) / J&J, Descovy (emtricitabine/tenofovir alafenamide) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
Changes in behavioral self reported outcomes in a cohort of patients with primary HIV infection (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_373;
In this cohort of PLWH at high risk of HIV transmission, the initiation of care and start of ART decreased the need to disclose HIV status to sexual partner, without substantial changes in engaging in risky sexual behaviour. This finding strongly suggests the need to achieve viral suppression as quickly as possible and to adopt, especially in the first year after starting ART, targeted behavioural and biomedical prevention strategies.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
Persistence on guideline-recommended HIV treatment: comparison among US Medicaid beneficiaries newly initiating treatment with single- versus multiple-tablet regimens (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_372;
Among adult US Medicaid beneficiaries living with HIV and newly prescribed ART, persistence was statistically significantly higher among STR initiators compared to MTR initiators. Amongst those on STRs, specifically B/F/TAF, persistence was significantly higher as compared to MTRs (F/TDF+DTG and F/TAF+DTG).
- Tivicay (dolutegravir) / ViiV Healthcare
Preferences and uptake of mHealth supported multi-month ART distribution among adults living with HIV in rural Lesotho: a cross-sectional survey (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_305;
P=N/A
Uptake of mHealth support options was high among participants reporting access to a cell phone. A mHealth supported MMD package will be assessed for clinical outcomes and cost-effectiveness in the ongoing VITAL trial.
- Tivicay (dolutegravir) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD)
SARS-CoV-2 infection in HIV-infected solid organ transplant recipients. A retrospective cohort study (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_270;
All disease was mild; one asymptomatic patient died suddenly one month after infection. Multicentre studies should confirm these results
- bictegravir (GS-9883) / Gilead
Hepatic steatosis associated with integrase strand transfer inhibitors - does the substance matter? (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_228;
BIC seems to be more favourable in the context of HS, but we were not able to detect a significant difference between the four groups. 63 (57.3%), 5 (4.5%), 27 (24.5%) and 15 (13.6%) participants were treated with dolutegravir (DTG)-, boosted elvitegravir (EVG)-, raltegravir (RAL)-, or bictegravir (BIC) in the observational period, respectively.
- bictegravir (GS-9883) / Gilead
Screening and short-course treatment for latent tuberculosis infection among people living with HIV who received integrase inhibitor-based antiretroviral therapy (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_206;
Furthermore, the respective proportions were similarly high (98.8–100%) in those concurrently receiving bictegravir- and dolutegravir-containing regimens (). Short-course rifapentine-based regimens had high completion rates and acceptable adverse events without negative impact on virologic response among PLWH who concurrently received integrase inhibitor-based ART.
- Tivicay (dolutegravir) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD)
Efficacy and safety of efavirenz, raltegravir and dolutegravir in HIV/TB co-infection. A retrospective cohort study (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_204;
We included all patients co-infected with HIV and tuberculosis starting a rifampicin-based regimen, with a plasma viral load (VL)>1000 copies/mL. In this retrospective study, raltegravir and dolutegravir yielded similar efficacy and safety results to efavirenz for the treatment of patients co-infected with HIV and TB.
- Comorbidities and antiretroviral utilization among people living with HIV in the United States (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_177;
A consistent ART utilization pattern was observed across comorbidity subpopulations of PLWH. Given the potential for drug-condition interactions with ART, an individualized approach to care based on clinical characteristics could minimize the risk of adverse events and exacerbation of pre-existing conditions.
- lenacapavir (GS CA2) / Gilead
Subgroup efficacy analyses of long-acting subcutaneous lenacapavir in phase 2/3 in heavily treatment-experienced people with HIV (CAPELLA study) (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_140;
Purpose: Lenacapavir (LEN), a potent first-in-class inhibitor of HIV-1 capsid function, is in development as a long-acting agent for treatment and prevention of HIV-1. In the ongoing Phase 2/3 study (CAPELLA) in heavily treatment-experienced (HTE) people with HIV-1 (PWH) with multidrug-resistance with ongoing viremia (≥ 400 copies/mL) (Figure), LEN demonstrated potent antiviral activity during the functional monotherapy period (1.9 log decline) and led to high rates of virologic suppression in combination with an optimized background regimen (OBR) at Week 26 (81%).
- dolutegravir/emtricitabine/tenofovir alafenamide (DTG/FTC/TAF) / Mylan, Tivicay (dolutegravir) / ViiV Healthcare
Week 192 bone and renal markers from the ADVANCE trial (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_133;
Fifteen bone fractures occurred during the study period, none attributed to the study drugs. Between baseline and week 48, hip BMD decreased significantly in all treatment groups, with, greater reductions in the TDF-containing groups versus the TAF-containing group (P < 0.001).
- Aikening (albuvirtide) / Frontier Biotechnologies
Albuvirtide-based dual therapy for hospitalised AIDS patients is safe and effective: a real-world cohort study (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_126;
Data suggests that ABT-dual is safe and effective for hospitalised AIDS patients. In view of the rapid viral load suppression and restoration of CD4+ count in 8 weeks of treatment, its clinical application warrants further investigation.
- Dovato (dolutegravir/lamivudine) / ViiV Healthcare, Tivicay (dolutegravir) / ViiV Healthcare
Switch strategy with dolutegravir plus lamivudine in routine clinical practice: persistance and efficacy at 48 and 96 weeks (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_122;
Overall, 358 patients were selected: women 68 (19%) and median age 51.7 years. Median time since HIV diagnosis and median time on ART were 13.4 and 10.1 years, respectively.
- Tivicay (dolutegravir) / ViiV Healthcare
An observational, multicentric study to evaluate early mortality in severely ill AIDS patients treated with efavirenz or dolutegravir in Brazil (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_99;
184 patients were enrolled, 92 per arm. Mean baseline CD4 cells count was similar for DTG (22.8±14.3) and EFV (22.8±14.1) groups, as well the proportion of males (65%), and plasma viral load (PVL) (5.9 copies/ml log10 each group).
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
A simplified approach to antiretroviral therapy with biktarvy among inner-city vulnerable residents with HIV infection: living up to the promise of 90-90-90 (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_97;
A disproportionate number of vulnerable inner-city residents exhibit incomplete responses to antiretroviral therapy. We have shown that this can be successfully addressed through the administration of simpler, more potent antiretroviral regimens in the context of patient-centered multidisciplinary models of care.
- bictegravir (GS-9883) / Gilead
Weight gain after switching to integrase inhibitor-based ART is not associated with hepatic steatosis in HIV-infected patients (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_91;
Purpose: Weight gain is associated with integrase inhibitors (INSTI)-based regimens, particularly when combined with tenofovir alafenamide (TAF)...However, switching from efavirenz to raltegravir was not associated with HS, despite weight gain after the switch...Of them, 67 (43%) switched to dolutegravir, 47 (31%) to raltegravir, 22 (14%) to bictegravir and 18 (12%) to elvitegravir-cobicistat... Weight gain in HIV-infected patients after switching to INSTI-based regimens is not paralleled by changes in HS one year after the switch.Weight gain associated after switching to INSTI-based regimens does not parallel to an increase in HS in HIV-infected patients one year after the switch.
- Tivicay (dolutegravir) / ViiV Healthcare
Transitioning to dolutegravir: virological outcomes in an HIV cohort in rural Tanzania (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_88;
This underlines the importance of programmatic uptake of DTG-based ART in LMICs. LTFU remains high and potentially jeopardizes control of the HIV epidemic.
- Tivicay (dolutegravir) / ViiV Healthcare
Body weight evolution among HIV-infected patients starting antiretroviral therapy with dolutegravir or efavirenz based regimens in rural Tanzania (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_82;
Initiating a dolutegravir-based ART regimen was associated with more weight gain compared to efavirenz-based regimens after 12 months, confirming observations from industrialized settings. Weight gain of ≥10% was associated with the use of dolutegravir, level of immunosuppression, BMI at ART initiation and being female.
- Tivicay (dolutegravir) / ViiV Healthcare
HIV-1 pretreatment drug resistance negatively impacts the outcome of first-line antiretroviral treatment – week 96 results from the ITREMA trial (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_81;
Presence of PDR significantly increased the risk of virological failure of EFV-based ART. Accumulation of drug resistance mutations and reduced rates of viral load re-suppression on the same regimen after failure illustrates the profound impact of PDR.
- Tivicay (dolutegravir) / ViiV Healthcare
Dolutegravir-based dual therapy (DT): real-life data in cART-experienced patients (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_77;
All cART-experienced patients starting DTG/3TC or DTG/RPV from 01–2015 to 01–2021 at our Institution were included. In our cohort of ART-experienced patients, DTG-based DT was offered to patients with a long cART-exposure with good tolerance and a high probability of virological success also in patients with RT-mutations at cumulative genotype; no significant modifications in CD8 activated T-cells and plasma lipids were observed.
- Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J, Edurant (rilpivirine) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
2 year outcomes of dolutegravir/rilpivirine in virologically suppressed HIV-infected PLHIV: real-world data from the German JUNGLE cohort (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_74;
Overall, 11% of individuals discontinued DTG/RPV due to ADRs, with only 1% in the 2nd year. This was consistent with a statistically significant improved treatment satisfaction score in patients remaining on DTG/RPV for two years.
- bictegravir (GS-9883) / Gilead
Increasing trend of pretreatment integrase inhibitors resistance in a cohort of antiretroviral therapy-naïve people living with HIV (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_54;
The only factor associated with InSTI resistance was HIV-1 subtype non-B. Prevalence of at least low-level InSTI DR was anecdotal between 2009–2013 and then gradually raised from 1.3% in 2014 to 3.9% in 2019 (p-for-trend<0.001); prevalence of at least intermediate InSTI DR increased from 0% in 2009 to 2% in 2019 (p-for-trend=0.188, ).
- || Tivicay (dolutegravir) / ViiV Healthcare
Clinical, Journal: Protocol for active safety monitoring of a cohort of patients using a dolutegravir-based antiretroviral regimen in Mozambique. (Pubmed Central) - Sep 17, 2021
Written informed consent is obtained from each participant who agrees to participate to have their information collected, analysed and stored. Findings will be reported to the Ministry of Health and participating health centres to inform policy and practice as well as disseminated by peer-review publications.
- || Tivicay (dolutegravir) / ViiV Healthcare
Clinical, Journal: The Potential Teratogenicity Alert for Women Conceiving on Dolutegravir-Based Regimens: An Assessment of Risk Communication by an Urban HIV Clinic in Uganda and Choices made by Women. (Pubmed Central) - Sep 16, 2021
The process developed by the clinic can act as a model for response during drug safety alerts. Women made informed decisions with most opting to remain taking dolutegravir; however, effective contraception uptake was low.
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: Rollout of dolutegravir-based antiretroviral therapy in sub-Saharan Africa and its public health implications. (Pubmed Central) - Sep 11, 2021
Women made informed decisions with most opting to remain taking dolutegravir; however, effective contraception uptake was low. No abstract available
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: Mechanistic Analysis of the Broad Antiretroviral Resistance Conferred by HIV-1 Envelope Glycoprotein Mutations. (Pubmed Central) - Sep 9, 2021
We previously reported that, in vitro, the lab-adapted HIV-1 NL4-3 strain can acquire resistance to the integrase inhibitor dolutegravir (DTG) by acquiring mutations in the envelope glycoprotein (Env) that enhance viral cell-cell transmission...We observed that many Env mutations accumulated in individuals failing integrase inhibitor therapy despite a low frequency of resistance mutations in integrase. Our findings suggest that broad-based Env-mediated drug resistance may impact therapeutic strategies and provide clues toward understanding how ARV-treated individuals fail therapy without acquiring mutations in drug target genes.
- || Tivicay (dolutegravir) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD), Vitekta (elvitegravir) / Japan Tobacco, Gilead
Clinical, Journal: Structural effects of HIV-1 subtype C integrase mutations on the activity of integrase strand transfer inhibitors in South African patients. (Pubmed Central) - Sep 8, 2021
Molecular modeling and docking showed that RAMs and polymorphisms associated with INSTI-based therapy affect protein stability and this is supported by their weakened hydrogen-bond interactions compared to the wild-type. To the best of our knowledge, this is the first study to identify a double mutant in the 140's loop region from South African HIV-1C isolates and study its effects on Raltegravir, Elvitegravir, and Dolutegravir binding.Communicated by Ramaswamy H. Sarma.
- | Tivicay (dolutegravir) / ViiV Healthcare
Enrollment open: IMPAACT4TB: Safety Tolerability DDI Short Course Treatment of LTBI Infection With High-dose Rifapentine and Isoniazid or Standard Isoniazid Preventive Therapy in HIV+ Patients (DOLPHIN & DOLPHIN TOO) (clinicaltrials.gov) - Sep 8, 2021
P1/2, N=135, Recruiting, Sponsor: The Aurum Institute NPC
To the best of our knowledge, this is the first study to identify a double mutant in the 140's loop region from South African HIV-1C isolates and study its effects on Raltegravir, Elvitegravir, and Dolutegravir binding.Communicated by Ramaswamy H. Sarma. Active, not recruiting --> Recruiting
- || Tivicay (dolutegravir) / ViiV Healthcare
Clinical, P4 data, Journal: Safety and Effectiveness Analysis of Dolutegravir in Patients with HIV-1: Interim Report of Post-Marketing Surveillance in Japan. (Pubmed Central) - Sep 8, 2021
Active, not recruiting --> Recruiting The results of the survey identified no new safety and effectiveness risks in Japanese patients with HIV/AIDS treated with DTG.
- || Tivicay (dolutegravir) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD)
Clinical, Journal: First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens. (Pubmed Central) - Sep 4, 2021
The results of the survey identified no new safety and effectiveness risks in Japanese patients with HIV/AIDS treated with DTG. As African countries transition to dolutegravir-based regimens, prior raltegravir-exposure may prompt selection (and potential transmission) of dolutegravir-resistance, supporting case surveillance.
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: Dolutegravir derivative inhibits proliferation and induces apoptosis of non-small cell lung cancer cells via calcium signaling pathway. (Pubmed Central) - Sep 3, 2021
Finally, DTHP effectively inhibited tumor growth in the mouse xenograft model of lung cancer with low toxicity to normal organs. Taken together, our work identified DTHP as a superior antitumor agent, which will provide a novel strategy for the treatment of NSCLC with potential clinical application.
- | Prezista (darunavir) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
Trial completion date, Trial primary completion date: Body Composition Sub-study of the D2EFT Trial (clinicaltrials.gov) - Sep 2, 2021
P4, N=300, Recruiting, Sponsor: Kirby Institute
Taken together, our work identified DTHP as a superior antitumor agent, which will provide a novel strategy for the treatment of NSCLC with potential clinical application. Trial completion date: Jan 2022 --> Jan 2024 | Trial primary completion date: Jan 2022 --> Jan 2023
- | bictegravir (GS-9883) / Gilead
Journal: Weight gain following antiretroviral therapy (ART) initiation in ART-naïve people living with HIV in the current treatment era. (Pubmed Central) - Sep 1, 2021
Trial completion date: Jan 2022 --> Jan 2024 | Trial primary completion date: Jan 2022 --> Jan 2023 There is heterogeneity between regimens in weight gain following ART initiation among previously ART-naïve PLWH; we observed greater gain among PLWH taking newer INSTIs (DTG, BIC) and DRV-based regimens.
- ||| Tivicay (dolutegravir) / ViiV Healthcare, GSK3640254 / ViiV Healthcare
Enrollment open, Combination therapy: DYNAMIC: A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive Adults (clinicaltrials.gov) - Aug 30, 2021
P2b, N=80, Recruiting, Sponsor: ViiV Healthcare
There is heterogeneity between regimens in weight gain following ART initiation among previously ART-naïve PLWH; we observed greater gain among PLWH taking newer INSTIs (DTG, BIC) and DRV-based regimens. Not yet recruiting --> Recruiting
- | Tivicay (dolutegravir) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD)
Journal: Limited HIV-1 Subtype C nef 3'PPT Variation in Combination Antiretroviral Therapy Naïve and Experienced People Living with HIV in Botswana. (Pubmed Central) - Aug 29, 2021
Dolutegravir (DTG) is a potent anti-HIV drug that is used to treat HIV globally...In addition, we generated separate integrase and nef gene sequences by Sanger sequencing of plasma samples from individuals with virologic failure (VF) while on a DTG/raltegravir (RAL)-based cART...Our study confirms the high conservation of the HIV-1 nef gene 3'PPT motif in 'real-world' patients and showed no differences in the motif according to VL suppression or INSTI-based cART failure. Future studies should explore other HIV-1 regions outside of the pol gene for associations with DTG failure.
- || bictegravir (GS-9883) / Gilead
Clinical, Review, Journal: Do All Integrase Strand Transfer Inhibitors Have the Same Lipid Profile? Review of Randomised Controlled Trials in Naïve and Switch Scenarios in HIV-Infected Patients. (Pubmed Central) - Aug 28, 2021
In naïve patients, RAL, DTG, and bictegravir (BIC) produce a similar, slight increase in lipids...No changes were observed in lipids by switching trials between INSTIs. In summary, RAL, DTG, and BIC have superior lipid profiles compared with boosted-PI, efavirenz, and EVG/c, in studies conducted in naïve participants, and they are associated with a clinically significant decrease in lipoproteins by switching studies.
- | BIT 225 / Biotron
New P2 trial: A study of the safety and efficacy of 6 months treatment with BIT225 and Combination Antiretroviral Therapy (cART) in patients with Human Immunodeficiency Virus-1 (HIV-1) compared to cART alone, including measurement of BIT225 in the blood, antiviral activity and immune markers. (EUDRACT) - Aug 27, 2021
P2, N=27, Not yet recruiting, Sponsor: Biotron Limited
- | Tivicay (dolutegravir) / ViiV Healthcare
Trial completion date: NAMSAL: Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings (clinicaltrials.gov) - Aug 27, 2021
P3, N=616, Completed, Sponsor: ANRS, Emerging Infectious Diseases
In summary, RAL, DTG, and BIC have superior lipid profiles compared with boosted-PI, efavirenz, and EVG/c, in studies conducted in naïve participants, and they are associated with a clinically significant decrease in lipoproteins by switching studies. Trial completion date: Aug 2019 --> Jul 2021
- | Tivicay (dolutegravir) / ViiV Healthcare
Trial completion date, Trial primary completion date: Evaluation of Third-line cART Regimen in Cambodia (3DICAM) (clinicaltrials.gov) - Aug 26, 2021
P2, N=54, Recruiting, Sponsor: ANRS, Emerging Infectious Diseases
Trial completion date: Aug 2019 --> Jul 2021 Trial completion date: Oct 2020 --> Apr 2022 | Trial primary completion date: Oct 2020 --> Apr 2022
- || Dovato (dolutegravir/lamivudine) / ViiV Healthcare, Tivicay (dolutegravir) / ViiV Healthcare
Clinical, Review, Journal, Real-world evidence: HIV Treatment with the Two-Drug Regimen Dolutegravir Plus Lamivudine in Real-world Clinical Practice: A Systematic Literature Review. (Pubmed Central) - Aug 25, 2021
Dolutegravir plus lamivudine minimally impacted renal function and had minimal impact on or improved lipid profiles and bone mineral density. This systematic review demonstrates that effectiveness and safety of dolutegravir plus lamivudine in clinical practice support data from randomized controlled trials with regard to high rates of virologic response, low rates of discontinuation, and a high barrier to resistance.
- || Enrollment closed, Trial completion date, Trial primary completion date, Adherence: Digital Health Feedback System for Longitudinal Measurement of Medication Adherence During Anti-Retroviral (ARV)Therapy (clinicaltrials.gov) - Aug 25, 2021
P4, N=100, Active, not recruiting, Sponsor: University of California, San Diego
This systematic review demonstrates that effectiveness and safety of dolutegravir plus lamivudine in clinical practice support data from randomized controlled trials with regard to high rates of virologic response, low rates of discontinuation, and a high barrier to resistance. Recruiting --> Active, not recruiting | Trial completion date: Jun 2021 --> Dec 2021 | Trial primary completion date: Jun 2021 --> Dec 2021
- | Tivicay (dolutegravir) / ViiV Healthcare
Preclinical, Journal: Absence of developmental and reproductive toxicity in animals exposed to dolutegravir. (Pubmed Central) - Aug 20, 2021
In a rat pre- and post-natal development study, where DTG exposure to the pups occurred during pregnancy and postnatally via milk, no malformations or other developmental abnormalities were observed. In these studies, no DTG-related effects occurred on fertility, embryonic (pre- and post-implantation loss, resorptions, abortions, and malformations) or fetal development where the multiples of exposure at the maximum recommended human dose were up to 27 times higher in rats or below the human exposure in rabbits.
- || Tivicay (dolutegravir) / ViiV Healthcare
Clinical, Review, Journal: Excessive Weight Gain Associated With Dolutegravir Initiation in a 10-Year-Old Female With Perinatally Acquired Human Immunodeficiency Virus: A Case Report and Review of the Literature. (Pubmed Central) - Aug 20, 2021
Understanding its potential short- and long-term sequelae in children is critically important. We report a case of excessive weight gain in a child with PHIV on DTG and provide a brief literature review.
- || Tivicay (dolutegravir) / ViiV Healthcare
Clinical, Journal: High levels of acquired HIV drug resistance following virological non-suppression in HIV-infected women from a high-risk cohort in Uganda. (Pubmed Central) - Aug 20, 2021
Whereas high levels of NNRTI mutations support the transition to dolutegravir, the presence of NRTI mutations especially TAMs may compromise dolutegravir-based regimens or other second-line ART options. The moderate VS prevalence and high HIVDR prevalence therefore calls for timely ART switching and intensive adherence counseling.
- | Journal: Changes in functional connectivity in people with HIV switching antiretroviral therapy. (Pubmed Central) - Aug 20, 2021
Changes in fMRI are evident in PWH without perceived neuropsychiatric complaints switching cART. fMRI may be a useful tool in assisting to elucidate the underlying pathogenic mechanisms of cART-related neuropsychiatric effects.
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: Lifetime antiretroviral exposure and neurocognitive impairment in HIV. (Pubmed Central) - Aug 20, 2021
A longer duration to integrase inhibitor intake was negatively related to cognition in this cohort. Our findings suggest that possible cognitive complications of long-term exposure to integrase inhibitors, in particular dolutegravir, should be closely monitored in PWH.
- || Tivicay (dolutegravir) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD), Vitekta (elvitegravir) / Japan Tobacco, Gilead
Clinical, Journal: Overall tolerability of Integrase Inhibitors in clinical practice: results from a multicenter Italian cohort. (Pubmed Central) - Aug 20, 2021
Our data confirm the good tolerability of INIs in clinical practice. Differences emerge between the three drugs in reasons for discontinuation.
- || Dovato (dolutegravir/lamivudine) / ViiV Healthcare, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
Clinical, Journal: Comparing lamivudine+dolutegravir and bictegravir/emtricitabine/tenofovir alafenamide as switch strategies: preliminary results from clinical practice. (Pubmed Central) - Aug 20, 2021
Conclusions Both optimization strategies showed high tolerability in the short term in experienced pts, with few differences between them. Further studies are needed to properly assess the matter.
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: New management approaches to tuberculosis in people living with HIV. (Pubmed Central) - Aug 20, 2021
While it is unequivocal that substantial progress has been made in early detection and treatment of HIV-associated TB, significant therapeutic challenges persist. To optimize the management and outcomes of TB in HIV, therapeutic approaches that target the pathogen as well as enhance the host response should be explored.
- || Tivicay (dolutegravir) / ViiV Healthcare
Clinical, Journal: Dolutegravir-based regimen for maintenance of viral suppression in people living with HIV: 48-week results in real life setting. (Pubmed Central) - Aug 20, 2021
Switching to a DTG-based regimen may be a key option for achieving and maintaining maximal virological suppression, even in patients showing residual viremia at baseline. Furthermore, the improvement in blood lipid profile and the overall tolerability observed in this study strongly support the use of these regimens in the ageing HIV population.